January 20, 2012
By:
Stephanie Sutton
Takeda has announced "strategic measures to achieve efficiencies for long-term growth", which includes cutting close to 3000 jobs, 2100 of which will come from Europe.
|
January 19, 2012
By:
Stephanie Sutton
ePT--the Electronic Newsletter of Pharmaceutical Technology
The generic-drugs market is poised to experience strong growth as key blockbuster products go off patent, but companies looking to benefit from this will have to be careful about the product segments where they compete, according to a report from Frost & Sullivan.
|
January 12, 2012
By:
Rich Whitworth
ePT--the Electronic Newsletter of Pharmaceutical Technology
Novartis Consumer Health has announced a voluntary recall of all lots of select, bottle-packaged configurations of Excedrin, NoDoz, Bufferin and Gas-X Prevention. The recall follows consumer complaints of chipped or broken pills and inconsistent bottle packaging line clearance practices that could lead to stray tablets, capsules or caplets from other Novartis products.
|
January 12, 2012
By:
Amy Ritter
ePT--the Electronic Newsletter of Pharmaceutical Technology
The US Pharmacopeia announced a draft standard containing best practices for ensuring that drugs can be traced to their original manufacturer, are not counterfeited or adulterated, and can be transported to their intended destination without compromising quality.
|
January 12, 2012
By:
Stephanie Sutton
ePT--the Electronic Newsletter of Pharmaceutical Technology
Bristol-Myers Squibb (BMS) has signed an agreement to acquire the clinical-stage biotechnology company Inhibitex in a deal worth approximately $2.5 billion. The transaction will provide BMS with a potential candidate currently in Phase II development for the treatment of hepatitis C.
|
January 5, 2012
By:
Stephanie Sutton
ePT--the Electronic Newsletter of Pharmaceutical Technology
The FDA has released a new draft guidance that offers recommendations to companies wishing to respond to unsolicited requests for off-label information, including requests made via social media websites.
|
January 5, 2012
By:
Patricia Van Arnum
ePT--the Electronic Newsletter of Pharmaceutical Technology
Ben Venue Laboratories is extending its voluntary suspension of manufacturing at its Bedford, Ohio, facility. The company had originally announced the suspension on Nov. 19, 2011, and announced the extension of the suspension on Dec. 23, 2011.
|
|
January 2, 2012
By:
Rich Whitworth, Stephanie Sutton
Pharmaceutical Technology
Industry experts discuss formulation and technical challenges in multilayer tablet manufacture.
|
|
January 2, 2012
By:
Amy Ritter
Pharmaceutical Technology
Creating a successful antibody-drug conjugate requires careful selection of the drug, antibody, and linker.
|
|
